Organisation paid for research Program year 2025 Source: CMS Open Payments

Vaught Neurological Services

Neither a doctor nor a teaching hospital

Research payments

$304,752

23 payments

Through program year 2025, Vaught Neurological Services is reported as receiving $304,752 in research payments, across 23 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$35,525	3
2024	Research	$40,192	4
2023	Research	$14,595	2
2022	Research	$129,087	8
2021	Research	$85,353	6

Breakdown

Who paid Research payments · program years 2021–2025

Amgen Inc. $265,779 20 payments
Novartis Pharmaceuticals Corporation $37,589 1 payment
E.R. Squibb & Sons, L.L.C. $1,383 2 payments

Studies the money was for Research payments · program years 2021–2025

US Pt Satisfaction $66,268 5 payments
Ph3 Pediatric CM Study $48,669 4 payments
Phase P3 Pediatric Study (EM) $48,387 2 payments
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $37,589 1 payment
Ph3 Pediatric CM Study. $27,446 2 payments
Phase P3 Pediatric Study (EM). $21,669 2 payments
Phase P3 Pediatric Study EM $17,815 2 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $16,288 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) $11,857 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) $7,381 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.